<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478112</url>
  </required_header>
  <id_info>
    <org_study_id>BioPro-RCMI-1505</org_study_id>
    <secondary_id>N° IdRCB : 2015-A01041-48</secondary_id>
    <nct_id>NCT02478112</nct_id>
  </id_info>
  <brief_title>Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)</brief_title>
  <acronym>BioPro-RCMI</acronym>
  <official_title>Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aquilab SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of dose escalation in radiotherapy (RT) for biochemical control of prostate&#xD;
      cancer is a clearly established fact based on the results of different published prospective&#xD;
      trials. This benefit, acquired with three-dimensional conformal radiation technique is&#xD;
      counterbalanced by an increase in urinary and gastrointestinal toxicity. The joint progress&#xD;
      of dose planning systems and multileaf collimators (MLC) technology have enabled the&#xD;
      Intensity Modulated Radiation Therapy (IMRT). Recently the contribution of &quot;spacers&quot;&#xD;
      positioned in the septum between the rectum and the prostate could improve the functional&#xD;
      results of IMRT in terms of rectal toxicity.&#xD;
&#xD;
      The aim of the investigators study is to assess the dosimetric gain from the contribution of&#xD;
      the implantable BioProtect balloon on organs at risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for the trial and having signed their consent to participate will undergo a&#xD;
      scan to verify the possibility of implantation of the balloon. Before and after implantation&#xD;
      of the balloon, a dosimetric scan will be performed. Radiotherapy will be administered&#xD;
      according to the habits of each centre : Intensity modulated radiotherapy : 2 Gy / session, 5&#xD;
      weekly sessions, total dose of 74-80 Gy (+/- associated with an hormone therapy).&#xD;
&#xD;
      Patients will have a clinical examination :&#xD;
&#xD;
        -  prior to the start of treatment&#xD;
&#xD;
        -  once a week during the radiotherapy&#xD;
&#xD;
        -  at the end of the radiotherapy&#xD;
&#xD;
        -  and at the end of the study.&#xD;
&#xD;
      They will also complete quality of life questionnaires :&#xD;
&#xD;
        -  prior to the start of treatment&#xD;
&#xD;
        -  at mid-treatment&#xD;
&#xD;
        -  at the end of the radiotherapy&#xD;
&#xD;
        -  and at 3, 6, 12 and 24 months after the end of the radiotherapy.&#xD;
&#xD;
      Finally, patients will undergo a laboratory examination :&#xD;
&#xD;
        -  prior to the start of treatment&#xD;
&#xD;
        -  3 months after the end of the radiotherapy&#xD;
&#xD;
        -  and then every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">November 25, 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosimetric gain from the contribution of the balloon on organs at risk</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation by comparison of the dosimetric scans performed before and after the implantation of the balloon.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary and rectal toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Urinary and rectal toxicity evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stages of the implantation of the Bioprotect balloon</measure>
    <time_frame>1 week</time_frame>
    <description>Monitoring of the balloon by Cone Beam Computed Tomography during the radiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical feasibility of the implantation of the Bioprotect balloon</measure>
    <time_frame>1 week</time_frame>
    <description>Monitoring of the balloon by Cone Beam Computed Tomography during the radiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by QLQ-C30</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life measured by the QLQ-C30 questionnaire of the EORTC (European Organisation for Research and Treatment of Cancer) and by the QLQ-C30 PR25 module and the International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Biodegradable Balloon Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biodegradable balloon implanted before radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biodegradable balloon implant</intervention_name>
    <description>Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer</description>
    <arm_group_label>Biodegradable Balloon Implant</arm_group_label>
    <other_name>BioProtect Balloon Implant System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient over 18 years old&#xD;
&#xD;
          2. With a localized adenocarcinoma of the prostate&#xD;
&#xD;
               -  of intermediate risk of D'AMICO&#xD;
&#xD;
               -  and of stage MRI &lt; T3&#xD;
&#xD;
          3. Requiring a treatment with Intensity Modulated Radiotherapy&#xD;
&#xD;
          4. PSA (Prostate-Specific Antigen) levels ≤ 20 ng/mL before external beam radiotherapy&#xD;
&#xD;
          5. Prostate volume &gt; 15 cc&#xD;
&#xD;
          6. Short hormone therapy possibly associated (4-6 months)&#xD;
&#xD;
          7. Patient without clinical signs of progressive disease (Performing a bone scan and a CT&#xD;
             scan is optional)&#xD;
&#xD;
          8. Performance status ECOG (Eastern Cooperative Oncology Group) ≤ 1&#xD;
&#xD;
          9. Life expectancy ≥ 10 years&#xD;
&#xD;
         10. Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incompatibility to the implantation of a Bioprotect balloon :&#xD;
&#xD;
               -  ongoing anticoagulant by vitamin K antagonist (VKA) or heparintherapy&#xD;
&#xD;
               -  patient with immunosuppression or with serious chronic diseases such as heart&#xD;
                  failure, cirrhosis, chronic kidney failure, colic or rectal digestive&#xD;
                  inflammatory disease&#xD;
&#xD;
               -  history of prostatitis or of lower gastrointestinal infection treated or ongoing&#xD;
&#xD;
               -  history of recto-colic inflammatory disease or of repeated prostatic resections&#xD;
&#xD;
               -  untreated perineal wound&#xD;
&#xD;
          2. Prior treatment with hormone therapy&#xD;
&#xD;
          3. History of another invasive cancer within 5 years prior to study entry (with the&#xD;
             exception of a treated basal cell skin carcinoma)&#xD;
&#xD;
          4. History of pelvic radiotherapy&#xD;
&#xD;
          5. Severe hypertension non controlled by an adapted treatment (≥ 160 mm Hg in systole&#xD;
             and/or ≥ 90 mm Hg in diastole)&#xD;
&#xD;
          6. Ongoing antineoplastic therapy&#xD;
&#xD;
          7. Person deprived of liberty or under tutorship&#xD;
&#xD;
          8. Inability to submit to the medical monitoring of the study for geographical, social or&#xD;
             psychological reasons.&#xD;
&#xD;
          9. Conformal radiotherapy without intensity modulation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David PASQUIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <zip>59187</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Levallois-Perret</city>
        <zip>92309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Cancérologie Paris Nord</name>
      <address>
        <city>Sarcelles</city>
        <zip>95200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intensity Modulated Radiotherapy</keyword>
  <keyword>Balloon implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

